Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations

International Journal of Antimicrobial Agents

Volumn 44, Issue 6, 2014, Pages 557-563

  Paladino, Joseph A ^a,b,c   Jacobs, David M ^a,b   Shields, Ryan K ^d   Taylor, Jerusha ^e   Bader, Justin ^a   Adelman, Martin H ^b   Wilton, Greg J ^b   Crane, John K ^c,f   Schentag, Jerome J ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b CPL Associates LLC   (United States)

^c ERIE COUNTY MEDICAL CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f UNIVERSITY AT BUFFALO   (United States)

Author keywords

Ceftaroline fosamil; MRSA bacteraemia; Vancomycin

Indexed keywords

CEFTAROLINE; DAPTOMYCIN; LINEZOLID; RIFAMPICIN; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; GLYCOPEPTIDE; PPI-0903;

ABDOMINAL INFECTION; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL ENDOCARDITIS; BACTERIAL SKIN DISEASE; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DEVICE INFECTION; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HEALTH CARE ASSOCIATED PNEUMONIA; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OSTEOMYELITIS; RECOMMENDED DRUG DOSE; RECURRENT INFECTION; RETROSPECTIVE STUDY; VERY ELDERLY; BACTEREMIA; CLINICAL TRIAL; COMPARATIVE STUDY; DEMOGRAPHY; DISEASE ERADICATION; DRUG EFFECTS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTICENTER STUDY; STAPHYLOCOCCAL INFECTIONS; TIME FACTOR; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; CASE-CONTROL STUDIES; CEPHALOSPORINS; DEMOGRAPHY; DISEASE ERADICATION; FEMALE; GLYCOPEPTIDES; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; TIME FACTORS; TREATMENT FAILURE; VANCOMYCIN;

EID: 84911888411     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2014.07.024     Document Type: Article

References (15)

1. W.R. Jarvis, A.A. Jarvis, and R.Y. Chinn National prevalence of methicillin-resistant Staphylococcus aureus in inpatients at United States health care facilities, 2010 Am J Infect Control 40 2012 194 200
2. T.P. Lodise, J. Graves, A. Evans, E. Graffunder, M. Helmecke, and B.M. Lomaestro Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin Antimicrob Agents Chemother 52 2008 3315 3320
3. P.A. Moise, G. Sakoulas, A. Forrest, and J.J. Schentag Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia Antimicrob Agents Chemother 51 2007 2582 2586
4. S.J. van Hal, T.P. Lodise, and D.L. Paterson The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis Clin Infect Dis 54 2012 755 771
5. C. Liu, and H.F. Chambers Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods Antimicrob Agents Chemother 47 2003 3040 3045
6. A.C. Musta, K. Riederer, S. Shemes, P. Chase, J. Jose, and L.B. Johnson Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years J Clin Microbiol 47 2009 1640 1644
7. M.E. Steed, and M.J. Rybak Ceftaroline: a new cephalosporin with activity against resistant Gram-positive pathogens Pharmacotherapy 30 2010 375 389
8. H.M. Polenakovik, and C.M. Pleiman Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature Int J Antimicrob Agents 42 2013 450 455
9. J.S. Garner, W.R. Jarvis, T.G. Emori, T.C. Horan, and J.M. Hughes CDC definitions for nosocomial infections, 1988 Am J Infect Control 16 1988 128 140
10. J.A. Paladino, and R.E. Fell Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial pneumonia Ann Pharmacother 28 1994 384 389
11. Forest Laboratories Teflaro (ceftaroline) package insert 2013 Forest Laboratories New York, NY
12. Y.M. Wi, J.M. Kim, E.J. Joo, Y.E. Ha, C.I. Kang, and K.S. Ko High vancomycin minimum inhibitory concentration is a predictor of mortality in meticillin-resistant Staphylococcus aureus bacteraemia Int J Antimicrob Agents 40 2012 108 113
13. C.L. Moore, P. Osaki-Kiyan, N.Z. Haque, M.B. Perri, S. Donabedian, and M.J. Zervos Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study Clin Infect Dis 54 2012 51 58
14. K.P. Murray, J.J. Zhao, S.L. Davis, R. Kullar, K.S. Kaye, and P. Lephart Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study Clin Infect Dis 56 2013 1562 1569
15. S.Y. Park, I.H. Oh, H.J. Lee, C.G. Ihm, J.S. Son, and M.S. Lee Impact of reduced vancomycin MIC on clinical outcomes of methicillin-resistant Staphylococcus aureus bacteremia Antimicrob Agents Chemother 57 2013 5536 5542